The print · 8-K and call2026-11-05 · Pre-market
Revenue$68M
est. —
EPS—
est. —
Guidance · FY revenue$385.0M–$415.0M
vs consensus +4.2% · Consensus $383.9M
Novavax, Inc. · Biotechnology
NVAX Novavax, Inc. · Earnings
Reports 2026-11-05 Pre-market · ThuReaction day 11-05reported · reaction in progress
Get NVAX's results by email the night it reports
EPS and revenue vs. estimates, plus the first-day move. Free — unsubscribe in one click.
Report card
Done· 8-K + call· 11-05 Pre-marketBreakdown
Key figures, the focus-point check, management quotes, the sector read and the grade are in the full view. Start 30-day free trial →
Reaction
Now· open / day / 5-day· 11-05 → day 5Reactionreaction not yet settled
After-hours move—pre-market print, no after-hours read
Open / day close— / —
5 days later—day 5 pending
Sector XLV over the same window: open +0.9% / close −2.5%
Going in
Done· T-7 → T-1 freezeBefore the print · expectationsfrozen at T-1
No past prints on file yet.
What the record doesn't tell you
Which way does NVAX go on 11‑05?
- Model lean for 11-05, and the evidence behind it
- Move band, P10 – P90
- Last 8 prints, quarter by quarter
- Peers that already reported, and how they traded
Lean, stance and evidence on this page are model outputs, not investment advice. Trade at your own risk. Disclaimer →
Novavax earnings review: what the record says
Novavax (NVAX) reported earnings on Nov 5, 2026, before the open. The company posted revenue of $68M.
Figures come from NextPick's earnings-reaction ledger and the options market. Not investment advice.